Download NURS 520 Module 1 Tutoring and more Exams Nursing in PDF only on Docsity!
NURS 520 Module 1 Tutoring
SECTION 1: INTRODUCTION TO PSYCHOPHARMACOLOGY – BASIC
PRINCIPLES (Questions 1-15) Q1. What is the primary focus of psychopharmacology? A. The study of psychological disorders B. The study of drugs used to treat psychiatric disorders and their effects on mood, behavior, and cognition C. The study of psychotherapy techniques D. The study of the nursing process Answer: B Rationale: Psychopharmacology is the scientific study of how drugs affect psychological functions—specifically mood, behavior, and cognition. This field is foundational for Psychiatric Mental Health Nurse Practitioners who prescribe psychotropic medications. Q2. A patient asks why the provider needs to know about their other medications before prescribing a new psychiatric medication. The nurse explains that this is important because: A. The provider wants to know which pharmacy the patient uses B. Drug interactions can alter the effectiveness or safety of psychiatric medications
C. The provider needs this information for billing purposes D. Psychiatric medications cannot be taken with any other drugs Answer: B Rationale: A complete medication history (including OTC drugs, supplements, and other prescriptions) is essential because drug-drug interactions can significantly alter the pharmacokinetics or pharmacodynamics of psychiatric medications, potentially leading to toxicity or treatment failure. Q3. The nurse understands that "off-label" prescribing of psychiatric medications refers to: A. Prescribing medications that are not FDA approved for any indication B. Prescribing an FDA-approved medication for a condition not specifically approved by the FDA C. Prescribing medications that are past their expiration date D. Prescribing medications without a valid license Answer: B Rationale: Off-label prescribing is common in psychiatry. It means using an FDA-approved drug for a different indication, at a different dose, or in a different population than what was specifically approved. This is legal and often evidence-based, but requires careful clinical judgment. Q4. A PMHNP is treating a 30-year-old male with major depressive disorder and prescribes an antidepressant that is FDA-approved for depression. The patient asks if this medication was "tested" on people
Rationale: The therapeutic window (or therapeutic index) is the dosage range between the minimum effective concentration (MEC) and the minimum toxic concentration (MTC). Drugs with a narrow therapeutic window require careful monitoring (e.g., lithium). Q6. A patient is prescribed a psychiatric medication that must be taken with food to reduce gastrointestinal upset. The patient takes the medication on an empty stomach and experiences nausea. This is an example of: A. A drug-drug interaction B. An idiosyncratic reaction C. A side effect related to the route and timing of administration D. A therapeutic effect Answer: C Rationale: Taking medication with food is a common strategy to reduce GI side effects. When the instruction is not followed, the expected side effect may occur. This is not an interaction or an idiosyncratic response—it's a predictable dose-related side effect. Q7. Which of the following is an example of a Schedule II controlled substance commonly used in psychiatry? A. Alprazolam (Xanax) B. Amphetamine salts (Adderall) C. Clonazepam (Klonopin) D. Sertraline (Zoloft) Answer: B
Rationale: In psychiatry, Schedule II drugs include stimulants (amphetamines, methylphenidate). Benzodiazepines (alprazolam, clonazepam) are Schedule IV. Sertraline is not a controlled substance. Q8. The Nurse Practice Act in Florida mandates that: A. All nurses can prescribe any medication B. APRNs must have a supervisory protocol with a physician for prescribing certain medications C. Prescribing is not regulated by the state D. Only physicians can prescribe psychiatric medications Answer: B Rationale: Florida's Nurse Practice Act outlines the scope of practice for APRNs, including prescribing authority. For controlled substances, a supervisory protocol or collaboration agreement is required. This is a legal requirement, not optional. Q9. The "chemical name" of a drug refers to: A. The brand name given by the manufacturer B. The exact molecular structure and chemical formula C. The official generic name D. The street name of the drug Answer: B Rationale: The chemical name describes the drug's molecular structure (e.g., "7-chloro- 1 - methyl- 5 - phenyl-1,3-dihydro-2H-1,4-benzodiazepin- 2 - one"). This is rarely used in clinical practice.
Q12. The "brand name" (trade name) of a medication is: A. The same as the chemical name B. The proprietary name given by the pharmaceutical company and protected by a patent C. The name used only in hospitals D. The generic name in Latin Answer: B Rationale: The brand name is the proprietary name chosen by the manufacturer (e.g., "Zoloft" for sertraline). It is protected by patent for a period of time, after which generic versions may be produced. Q13. When writing a prescription in Florida, which of the following is NOT a legal requirement? A. Patient's full name and date of birth B. Date the prescription was written C. The patient's Social Security number D. The prescriber's DEA number (for controlled substances) Answer: C Rationale: Florida prescription requirements include patient name/DOB, date, drug name, strength, quantity, directions, number of refills, prescriber signature, and DEA number for controlled substances. The patient's Social Security number is not required. Q14. The Florida Prescription Drug Monitoring Program (PDMP), E- FORCSE, is used primarily to:
A. Monitor over-the-counter medication sales B. Track controlled substance prescriptions to prevent "doctor shopping" and diversion C. Monitor medication prices D. Track immunization records Answer: B Rationale: Florida's E-FORCSE (Electronic-Florida Online Reporting of Controlled Substances Evaluation) database tracks Schedule II-IV controlled substance prescriptions. It is a critical tool for identifying potential misuse, diversion, or "doctor shopping" by patients obtaining prescriptions from multiple providers. Q15. A PMHNP is treating a patient who reports taking their medication inconsistently because "it's too expensive." What is the most appropriate first response? A. "You should stop taking the medication immediately." B. "Let's discuss cost concerns. We may be able to find a generic version, manufacturer coupon, or patient assistance program." C. "Cost is not a valid reason to skip medication." D. "Your insurance should cover it completely." Answer: B Rationale: Addressing cost barriers non-judgmentally is essential for treatment adherence. Many options exist (generic formulations, manufacturer coupons, patient assistance programs, 90-day supplies, or alternative medications). Judgmental or dismissive responses damage therapeutic alliance.
B. Involuntary functions such as heart rate, digestion, and respiration C. Cognitive processing D. Sensory perception Answer: B Rationale: The ANS is the "automatic" nervous system, controlling functions that typically occur without conscious effort: heart rate, blood pressure, digestion, sweating, pupil dilation, and respiratory rate. Q19. The sympathetic nervous system is often described as: A. Rest and digest B. Fight or flight C. Feed and breed D. Sleep and restore Answer: B Rationale: The sympathetic nervous system mobilizes the body during stress or threat, increasing heart rate, blood pressure, and respiration while diverting blood from digestion to skeletal muscles. Q20. A patient experiencing a panic attack has tachycardia, tachypnea, and dilated pupils. These symptoms are primarily due to activation of: A. The parasympathetic nervous system B. The sympathetic nervous system C. The somatic nervous system D. The enteric nervous system Answer: B
Rationale: Panic attacks trigger the "fight or flight" response via sympathetic activation, leading to symptoms such as rapid heart rate (tachycardia), rapid breathing (tachypnea), sweating, trembling, and dilated pupils. Q21. The parasympathetic nervous system is often described as: A. Fight or flight B. Rest and digest C. Stress response D. Voluntary movement Answer: B Rationale: The parasympathetic nervous system promotes calming, energy conservation, and "rest and digest" functions: slowing heart rate, increasing digestion, and promoting salivation. Q22. Acetylcholine is the primary neurotransmitter of the: A. Sympathetic nervous system at adrenergic receptors B. Parasympathetic nervous system at muscarinic and nicotinic receptors C. Central nervous system for dopamine pathways D. Somatic nervous system only Answer: B Rationale: Acetylcholine is the primary neurotransmitter of the parasympathetic nervous system (both preganglionic and postganglionic fibers) and the somatic nervous system. In the
Q25. The "synaptic cleft" is: A. The part of the neuron that produces neurotransmitters B. The microscopic gap between neurons across which neurotransmitters travel C. The protective covering of the axon D. The cell body of the neuron Answer: B Rationale: The synaptic cleft is the space between the presynaptic neuron (which releases neurotransmitter) and the postsynaptic neuron (which receives the signal). Neurotransmitters diffuse across this gap to bind to receptors. Q26. Which type of receptor is directly coupled to ion channels and mediates fast synaptic transmission? A. G-protein coupled receptors B. Ionotropic receptors C. Metabotropic receptors D. Tyrosine kinase receptors Answer: B Rationale: Ionotropic receptors (ligand-gated ion channels) contain an ion channel that opens directly when the neurotransmitter binds, producing very fast effects (milliseconds). Metabotropic receptors (G- protein coupled) produce slower effects via second messenger systems.
Q27. Metabotropic receptors (G-protein coupled receptors) differ from ionotropic receptors in that metabotropic receptors: A. Produce faster responses B. Activate second messenger systems, producing slower, longer- lasting effects C. Are not found in the nervous system D. Only bind to dopamine Answer: B Rationale: Metabotropic receptors are coupled to G-proteins that activate second messenger cascades (e.g., cAMP, IP3). This results in slower onset but more prolonged and diverse cellular effects compared to ionotropic receptors. Q28. The "resting membrane potential" of a neuron is approximately: A. +30 mV B. 0 mV C. - 70 mV D. - 90 mV Answer: C Rationale: The resting membrane potential is about - 70 mV (inside negative relative to outside). This is maintained by the Na⁺/K⁺ ATPase pump and selective permeability of the membrane to potassium. Q29. What occurs during depolarization of a neuron? A. Potassium rushes out of the cell
C. Glycine D. Serotonin Answer: B Rationale: Glutamate is the most abundant excitatory neurotransmitter in the CNS. It acts primarily on AMPA, NMDA, and kainate receptors. Excess glutamate can cause excitotoxicity. Q32. The primary inhibitory neurotransmitter in the central nervous system is: A. GABA (gamma-aminobutyric acid) B. Glutamate C. Dopamine D. Acetylcholine Answer: A Rationale: GABA (gamma-aminobutyric acid) is the primary inhibitory neurotransmitter in the CNS. It acts on GABA-A (ionotropic, fast inhibition) and GABA-B (metabotropic, slower inhibition) receptors. Q33. Glycine is an inhibitory neurotransmitter found primarily in the: A. Cerebrum B. Spinal cord and brainstem C. Basal ganglia D. Limbic system Answer: B
Rationale: Glycine is the primary inhibitory neurotransmitter in the spinal cord and brainstem. Strychnine is a glycine receptor antagonist that causes severe muscle spasms. Q34. The midbrain dopamine pathway that projects to the nucleus accumbens and is involved in reward, motivation, and addiction is the: A. Nigrostriatal pathway B. Mesolimbic pathway C. Mesocortical pathway D. Tuberoinfundibular pathway Answer: B Rationale: The mesolimbic pathway projects from the ventral tegmental area (VTA) to the nucleus accumbens. It is critical for reward processing and is implicated in addiction and psychosis (positive symptoms of schizophrenia). Q35. The nigrostriatal dopamine pathway projects from the substantia nigra to the striatum (caudate/putamen). Degeneration of this pathway is responsible for: A. Positive symptoms of schizophrenia B. Parkinson's disease C. Depression D. Anxiety Answer: B
Rationale: Lipophilic (fat-soluble) drugs diffuse readily across the BBB. Hydrophilic drugs, large molecules, and charged particles require specialized transport mechanisms or do not cross at all. Q38. A patient with a brain tumor receives chemotherapy. The nurse explains that some chemotherapy drugs cannot penetrate the brain tissue effectively due to: A. The patient's age B. The blood-brain barrier, which protects the brain but also limits drug delivery C. The drug being too lipophilic D. Rapid metabolism in the liver Answer: B Rationale: The BBB protects the brain from toxins but also prevents many potentially therapeutic drugs from reaching brain tissue. This is a significant challenge in treating brain tumors and CNS disorders. Q39. The mesocortical dopamine pathway projects from the ventral tegmental area (VTA) to the: A. Striatum B. Prefrontal cortex C. Hypothalamus D. Nucleus accumbens Answer: B
Rationale: The mesocortical pathway projects from the VTA to the prefrontal cortex. It is involved in cognitive control, motivation, and emotional regulation. Dysfunction may contribute to negative and cognitive symptoms of schizophrenia. Q40. The tuberoinfundibular dopamine pathway projects from the hypothalamus to the pituitary gland and primarily functions to: A. Control voluntary movement B. Inhibit prolactin release C. Regulate reward and motivation D. Control cognition Answer: B Rationale: The tuberoinfundibular pathway releases dopamine that inhibits prolactin secretion from the anterior pituitary. Antipsychotic drugs that block dopamine D2 receptors in this pathway cause elevated prolactin, leading to galactorrhea, gynecomastia, and sexual dysfunction. Q41. Which serotonin receptor subtype is most strongly associated with the therapeutic effects of atypical antipsychotics? A. 5-HT1A B. 5 - HT2A C. 5-HT D. 5-HT Answer: B
